Contribute Try STAT+ Today

Twice in recent months, a small Canadian company has approached two large drug makers to obtain licenses to manufacture Covid-19 vaccines so the shot could be distributed in low and middle-income countries where supplies are scarce.

But a request made to AstraZeneca (AZN) was ignored, while Johnson & Johnson (JNJ) denied the overture, according to executives at Biolyse. So now, the privately held company is asking the Canadian government to sidestep the vaccine patents in what could be a test of the willingness of a wealthy country to help ensure Covid-19 vaccine supplies reach impoverished corners of the globe.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • “If we could manufacture a vaccine already approved, it would save a great deal of time. And the transfer of know how would be the way to do it” said Biolyse president Brigitte Kiecken. How will a compulsory license provide for this transfer of know-how? A voluntary technology sharing platform like the WHO’s COVID-19 Technology Access Pool actually has the potential to provide for that.

    • Hi Paul,

      Thanks for the note and I agree with you that a license permitted by the Canadian government would not provide know how. But I believe she was referring to the notion of cooperation – that J&J or some other company would willingly allow Biolyse to proceed and provide some know how. File it under wishful thinking.

      And yes, C-TAP provides such an avenue, but unfortunately, hasn’t gotten off the ground. But I know that you know the reason.

      All best,
      ed at pharmalot

Comments are closed.